Rieger J - Search Results

1

Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients.

Rieger J, Bähr O, Müller K, Franz K, Steinbach J, Hattingen E. Rieger J, et al. J Neurooncol. 2010 Aug;99(1):49-56. doi: 10.1007/s11060-009-0098-8. Epub 2009 Dec 25. J Neurooncol. 2010. PMID: 20035366

2

Heterogeneity in malignant gliomas: a magnetic resonance analysis of spatial distribution of metabolite changes and regional blood volume.

Wagner M, Nafe R, Jurcoane A, Pilatus U, Franz K, Rieger J, Steinbach JP, Hattingen E. Wagner M, et al. Among authors: rieger j. J Neurooncol. 2011 Jul;103(3):663-72. doi: 10.1007/s11060-010-0443-y. J Neurooncol. 2011. PMID: 21061143

3

Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.

Bähr O, Hattingen E, Rieger J, Steinbach JP. Bähr O, et al. Among authors: rieger j. Neuro Oncol. 2011 Sep;13(9):1020-9. doi: 10.1093/neuonc/nor099. Epub 2011 Jul 31. Neuro Oncol. 2011. PMID: 21807668 Free PMC article.

4

Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study.

Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, Anti S, Steinbach JP, Pilatus U. Hattingen E, et al. Among authors: rieger j. Neuro Oncol. 2011 Dec;13(12):1349-63. doi: 10.1093/neuonc/nor132. Epub 2011 Sep 2. Neuro Oncol. 2011. PMID: 21890539 Free PMC article.

5

ERGO: a pilot study of ketogenic diet in recurrent glioblastoma.

Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M, Steinbach JP. Rieger J, et al. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ijo.2014.2382. Epub 2014 Apr 11. Int J Oncol. 2014. PMID: 24728273 Free PMC article. Clinical Trial.

6

Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma.

Bähr O, Harter PN, Weise LM, You SJ, Mittelbronn M, Ronellenfitsch MW, Rieger J, Steinbach JP, Hattingen E. Bähr O, et al. Among authors: rieger j. Neurology. 2014 Jul 15;83(3):227-34. doi: 10.1212/WNL.0000000000000594. Epub 2014 Jun 13. Neurology. 2014. PMID: 24928118

7

Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.

Tichy J, Spechtmeyer S, Mittelbronn M, Hattingen E, Rieger J, Senft C, Foerch C. Tichy J, et al. Among authors: rieger j. J Neurooncol. 2016 Jan;126(2):361-9. doi: 10.1007/s11060-015-1978-8. Epub 2015 Oct 30. J Neurooncol. 2016. PMID: 26518540

8

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O. Schaub C, et al. Among authors: rieger j. J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18. J Neurooncol. 2016. PMID: 27193554

9

To diet or not to diet - that is still the question.

Rieger J, Steinbach JP. Rieger J, et al. Neuro Oncol. 2016 Aug;18(8):1035-6. doi: 10.1093/neuonc/now131. Neuro Oncol. 2016. PMID: 27382118 Free PMC article. No abstract available.

10

Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

Rieger J, Bähr O, Ronellenfitsch MW, Steinbach J, Hattingen E. Rieger J, et al. J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28. J Clin Oncol. 2010. PMID: 20585096 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

762 results

Search Page

Filters